Cortigent - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים CRGT

Risks for Cortigent, Inc. (CRGT) are linked to costly R&D processes and the pace of stimulator development, which is confirmed by the relative year-over-year (LTM) revenue dynamics, where the value remains at . Stability is driven by the expansion of the Orion platform in neuropharmaceuticals and the implementation of neural interfaces for the restoration of motor control. Such innovations in the field of artificial vision allow the company to minimize financial dependencies.
Cortigent, Inc. (CRGT) - פילוחי מדדים ודוחות פיננסיים

Cortigent, Inc. occupies a high-tech neuromodulation niche where commercial success depends on passing rigorous FDA certification stages. By analyzing the year-over-year sales trajectory over a rolling four-quarter period, an investor sees smoothed revenue dynamics that neutralize seasonality and quarterly gaps, allowing for an assessment of the actual business scaling speed against the backdrop of venture financing and the absence of a mass market.